Announcements
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
- ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
- ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
- ResMed Secures Significant Victory in Patent Fight Against New York University
- Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
- ResMed Adopts New Operating Model to Accelerate Long-term Growth
More ▼
Key statistics
As of last trade Resmed Inc (RME:BRN) traded at 166.21, 0.00% below its 52-week high of 166.21, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 166.21 |
---|---|
High | 166.21 |
Low | 166.21 |
Bid | 164.07 |
Offer | 164.71 |
Previous close | 166.21 |
Average volume | -- |
---|---|
Shares outstanding | 147.09m |
Free float | 145.88m |
P/E (TTM) | 32.53 |
Market cap | 28.88bn USD |
EPS (TTM) | 6.04 USD |
Annual div (ADY) | 1.68 CHF |
---|---|
Annual div yield (ADY) | 1.01% |
Div ex-date | Feb 07 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Jan 30 2024.
More ▼